To determine whether rearrangements of repeat motifs during mitotic DNA replication of parasites create significant CSP diversity under conditions of low effective meiotic recombination rates, we examined csp alleles from sympatric P. vivax isolates systematically sampled from an area of low malaria endemicity in Brazil over a period of 14 months.
To explore the hypothesis that angiotensin II may play a role in the susceptibility to cerebral malaria (CM), we performed a genetic association study of malaria patients in Orissa, India analyzing three SNPs (ACE2 C → T, iNOS C → T, eNOS Glu → Asp) and two I/D polymorphisms (ACE I/D and IL-4 B1/B2).
No abstract available
No abstract available
Comparative evaluation, assay and model standardisation, greater sharing of information, collaboration and coordination between groups, and rigorous evaluation of existing datasets are steps that can be taken to enable reductions in empiricism over time.
During follow-up in antimalarial drug trials, treated subjects can be newly infected. PCR correction is used to distinguish this re-infection from drug failure (recrudescence) and to adjust final drug efficacy estimates.
The genome sequence of the malaria parasite Plasmodium falciparum was published in 2002 and revealed that not, vert, similar60% of its genes could not be assigned a function. Eight years later the majority of P. falciparum proteins are still of unknown function. We therefore present PlasmoPredict, an easy-to-use online gene function prediction tool that integrates a wide range of functional genomics data for P. falciparum to aid in the annotation of these genes.
In this opinion article, we examine how the toxicity of anticancer agents is just a matter of dose or ‘only dose makes the poison’, as coined in Paracelsus’ law. Thus, the opportunity exists to discover new antimalarials using the anticancer pharmacopoeia.
I conclude that MIM is still needed today to support African scientists’ investigator-initiated research and training.
The only clinical therapy against relapse of vivax malaria is the 8-aminoquinoline, primaquine. New, safer and more-easily administered drugs are urgently needed, and this is a crucial gap in the broader malaria-elimination agenda.